Table 3 |
||||
|
Adjusted1 Hazard Ratio for Overall and Disease-specific Survival |
||||
|
Risk Factors |
Overall Survival |
Disease-Specific Survival |
||
|
HR (95% CI) |
HR (95% CI) |
|||
|
|
||||
|
All Histologies N = 237 |
SCC N = 215 |
All Histologies N = 234 |
SCC N = 212 |
|
|
|
||||
|
p16 Status |
||||
|
p16- |
1.2 (0.7-2.2)1 |
0.9 (0.5-1.7) |
1.5 (0.7-3.1)1 |
1.0 (0.5-2.2) |
|
p16+ |
referent |
referent |
referent |
referent |
|
p53 Status |
||||
|
p53- |
referent |
referent |
referent |
referent |
|
p53+ |
1.4 (0.9-2.2)1 |
1.3 (0.8-2.2) |
1.9 (1.04-3.4)1 |
1.9 (1.01-3.5) |
|
HPV Status |
||||
|
HPV-HR |
referent |
referent |
referent |
referent |
|
HPV- |
2.1 (1.1-4.3)1 |
2.6 (1.2-5.3) |
1.6 (0.7-3.7)1 |
2.1 (0.9-4.8) |
|
p16/p53/HPV Status3 |
||||
|
p16+/p53-/HPV-HR |
referent |
referent |
referent |
referent |
|
p16-/p53-/HPV-HR |
NE3 |
NE3 |
NE3 |
NE3 |
|
p16+/p53+/HPV-HR |
1.6 (0.4-5.7) |
1.8 (0.5-6.3) |
0.9 (0.2-4.7) |
1.0 (0.2-5.3) |
|
p16-/p53+/HPV-HR |
3.2 (0.8-13.4) |
2.8 (0.7-11.5) |
3.9 (0.9-16.9) |
3.4 (0.8-14.9) |
|
p16-/p53+/HPV- |
4.1 (1.7-9.9) |
3.7 (1.5-9.0) |
4.0 (1.5-10.7) |
3.7 (1.4-9.9) |
|
p16+/p53-/HPV- |
2.9 (0.9-9.1) |
3.6 (1.1-11.1) |
1.7 (0.4-7.3) |
2.2 (0.5-9.2) |
|
p16-/p53-/HPV- |
3.1 (1.2-7.9) |
3.2 (1.2-8.2) |
1.9 (0.6-5.7) |
1.9 (0.6-5.9) |
|
p16+/p53+/HPV- |
3.4 (1.1-10.3) |
4.6 (1.4-14.5) |
2.9 (0.8-10.3) |
4.6 (1.3-16.1) |
|
Age2 |
1.03 (1.01-1.05) |
1.04 (1.02-1.1) |
1.03 (1.01-1.05) |
1.04 (1.01-1.1) |
|
Stage |
||||
|
I/II |
referent |
referent |
referent |
referent |
|
III/IV |
3.1 (1.7-5.9) |
3.1 (1.6-6.0) |
4.6 (1.9-10.9) |
4.5 (1.9-11.0) |
|
|
||||
|
1Adjusted for p16, p53, HPV, age, and stage; 2NE = not estimable due small sample size |
||||
|
Smith et al. Infectious Agents and Cancer 2010 5:4 doi:10.1186/1750-9378-5-4 |
||||
